Cargando…
Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib()()()
INTRODUCTION: C-Met plays important roles in treatment resistance, tumor invasion, and metastasis. In this study, we used a small molecule inhibitor of c-Met, crizotinib, in cetuximab-resistant, mutant KRAS-driven colorectal cancer cell lines and assessed radiosensitization. MATERIALS AND METHODS: A...
Autores principales: | Cuneo, Kyle C., Mehta, Ranjit K., Kurapati, Himabindu, Thomas, Dafydd G., Lawrence, Theodore S., Nyati, Mukesh K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226619/ https://www.ncbi.nlm.nih.gov/pubmed/30412912 http://dx.doi.org/10.1016/j.tranon.2018.10.005 |
Ejemplares similares
-
Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
por: Palma, Norma A., et al.
Publicado: (2014) -
Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy()
por: Ray, Dipankar, et al.
Publicado: (2015) -
Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors
por: Ray, Paramita, et al.
Publicado: (2016) -
Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?
por: Bridges, Alexander J., et al.
Publicado: (2021) -
Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)